课题基金 / 基金详情

MODULATION OF OPIOID AND NMDA RECEPTOR MRNA BY RIBOZYMES

MODULATION OF OPIOID AND NMDA RECEPTOR MRNA BY RIBOZYMES
核酶对阿片类药物和 NMDA 受体 mRNA 的调节
批准号:
2414623
负责人:
HUGH D ROBERTSON
金额:
$13.27万
依托单位国家:
美国
项目类别:
财政年份:
1996
资助国家:
美国
项目状态:
已结题
起止时间:
1996-06-01 至 1999-04-30

项目摘要

项目成果

HUGH D ROBERTSON的其他基金

相关文献

中文摘要
翻译
我们建议进行旨在适应核酶方法的研究
英文摘要
We propose to conduct research designed to adapt the ribozyme approach to provide a transient or permanent "knockout" of a target protein (and its associated function) by cleaving the appropriate mRNA with high specificity. This approach is one which is already showing promise in the antiviral field, where a number of advantages for it have emerged. RNA- level approaches in general are succeeding in antiviral therapy for hepatitis B virus, for example; the ribozyme approach is most promising because one ribozyme can attack a number of RNAs because of its catalytic/enzymatic properties. The other major approach-antisense inhibition--works at a 1:1 level. We propose to adapt approaches which are showing promise in the antiviral field to key cellular RNAs, including mRNAs for mouse delta opioid receptors (DORs) and glutamate receptor channel subunits (NMDAs) in test tube experiments using cloned mRNA expression vectors; and in cultured mouse nerve cells, specifically the NGl08-l5 cell line. We plan to test the hypothesis that the ribozyme technique, using either delta hepatitis agent ribozymes retargeted to the relevant mRNAs; or external guide sequences (EGSs) which re-target the cellular tRNA processing enzyme RNase P to exogenous sequences, can provide a transient "knockout" of a targeted mRNA, and its associated functional protein. The cellular approach is the logical endpoint of the initial research effort, with work in animals to follow. The collaborative efforts of the Robertson Lab (RNA structure/function; ribozyme development) and the Inturrisi Lab (mRNA and cell characterization; RNA detection) have already led to several publications in the field of RNA quantitation. We will collaborate on testing the above mRNAs, comparing the ribozyme approaches mentioned to parallel efforts using antisense deoxyribonucleotides. In this way we should be able to introduce these approaches into the field of drug abuse research, where they should allow an increase in systematic studies of the effects of expression involving various receptor genes.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
HCV INTERNAL RIBOSOME ENTRY SITE AS TARGET FOR THERAPY
HCV INTERNAL RIBOSOME ENTRY SITE AS TARGET FOR THERAPY
HCV INTERNAL RIBOSOME ENTRY SITE AS TARGET FOR THERAPY
HCV INTERNAL RIBOSOME ENTRY SITE AS TARGET FOR THERAPY